Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Videos

PlayVIDEO: Prof PG Steg Targeting PCSK9 inhibition

VIDEO: Prof PG Steg Targeting PCSK9 inhibition

read more »
PlayVIDEO: Prof Eric Bruckert EAS FHSC Registry

VIDEO: Prof Eric Bruckert EAS FHSC Registry

read more »
PlayVIDEO: Prof Eric Bruckert LDL goals in FH

VIDEO: Prof Eric Bruckert LDL goals in FH

read more »
PlayVIDEO: Novel PCSK9 therapeutics

VIDEO: Novel PCSK9 therapeutics

read more »
PlayVIDEO: BANTING study in type 2 diabetes: evolocumab improves lipid goals and postprandial lipids

VIDEO: BANTING study in type 2 diabetes: evolocumab improves lipid goals and postprandial lipids

Results from the BANTING study add to the evidence-base that PCSK9 inhibition is efficacious in improving lipid goal attainment in individuals with type 2 diabetes mellitus (T2DM) with hypercholesterolaemia or mixed dyslipidaemia. There were also favourable changes in postprandial lipids. Dyslipidaemia is one of the…

read more »
PlayVIDEO: AHA/ACC 2018 Cholesterol Guidelines also have good points

VIDEO: AHA/ACC 2018 Cholesterol Guidelines also have good points

Professor Anthony Wierzbicki (Guys and St. Thomas’ Hospital, London UK): A view of the AHA/ACC 2018 Cholesterol Guidelines The recent update to the AHA/ACC 2018 Cholesterol Guidelines has created much debate. Here, PCSK9 Forum Editor Professor Anthony Wierzbicki gives his view on one of the…

read more »
PlayVIDEO: Coronary artery calcium for stratifying risk in familial hypercholesterolaemia

VIDEO: Coronary artery calcium for stratifying risk in familial hypercholesterolaemia

Professor Raul Santos (Hospital Israelita Albert Einstein and University of São Paulo, Brazil): Is coronary artery calcium a tool for stratifying risk in familial hypercholesterolaemia? Professor Raul Santos discusses this pertinent question in the light of results from a recent cohort study in more than…

read more »
PlayVIDEO: PCSK9 Forum Inhibitors and Health Economics

VIDEO: PCSK9 Forum Inhibitors and Health Economics

The value of therapeutic intervention with a PCSK9 inhibitor is highly pertinent with increasingly finite resources for healthcare services. While PCSK9 inhibitors are undoubtedly extremely powerful LDL-lowering therapies that reduce cardiovascular events, their perceived cost has been a major barrier to uptake. The recent ODYSSEY…

read more »